<DOC>
	<DOCNO>NCT00191490</DOCNO>
	<brief_summary>Phase II study evaluate activity gemcitabine intravesical therapy marker lesion superficial bladder carcinoma intermediate risk . Primary objective evaluation pathological complete response 8 instillation gemcitabine . 46 patient request .</brief_summary>
	<brief_title>A Randomized Study Evaluating Feasibility Activity Three Different Combination With Gemcitabine First Line Therapy Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion Histologically cytologically confirm diagnosis NSCLC Patients must locoregionally advance unresectable non metastatic NSCLC Stage IIIB ( N3 supraclavicular T4 pleural effusion ) Stage IV accord revise International Staging System Patients must least one measurable lesion WHO Performance Status 0 1 Adequate Organ Function Exclusion criterion : Prior systemic chemotherapy immunotherapy include neoadjuvant adjuvant treatment Prior radiotherapy NSCLC Patients symptomatic brain metastasis leptomeningeal disease . However , patient symptomatic brain metastases become asymptomatic corticosteroid treatment enter study Current peripheral neuropathy NCI grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>